Q-omics provides the consensus-scored ZNF688 profile across patient tissues and cancer cell-line models. ZNF688 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZNF688 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF688 RNA expression shows 18,224 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where ZNF688 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF688 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF688 survival associations across molecular data types. ZNF688 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF688 RNA expression–survival associations across cancer types. High ZNF688 expression shows unfavorable associations in UVM, but favorable associations in UCEC, MESO, HNSC, PAAD and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ZNF688 RNA expression.
This table summarizes ZNF688 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF688. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF688 shows lower tumor expression in UCEC and COAD and higher tumor expression in KIRC, KIRP, BRCA and HNSC. The KIRC box plot shows higher ZNF688 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with ZNF688 in patient tissues and cancer cell lines. In patient samples, ZNF688 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF688 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
